Nevirapine

also known as NVP · Viramune · BI-RG-587 · BIRG 0587 · Neviparine · Nevirapina · Nevirapine anhydrous · Nevirapine teva · +8 more

Small molecule

Developed for: HIV infectious disease · tuberculosis · AIDS · lipodystrophy · HIV wasting syndrome · hyperlipoproteinemia · Kaposi's sarcoma · central nervous system disorder
+2 more
· dementia · hepatitis C virus infection
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Boehringer Ingelheim · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Bristol-Myers Squibb · Harvard School of Public Health (HSPH) · French National Agency for Research on AIDS and Viral Hepatitis
+85 more
· National Institute of Mental Health (NIMH) · Glaxo Wellcome · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Makerere University · AIDS Care Research in Africa · ANRS, Emerging Infectious Diseases · Abbott · Bamrasnaradura Infectious Diseases Institute · Centers for Disease Control and Prevention · Fight AIDS and Infectious Diseases Foundation · Germans Trias i Pujol Hospital · Gilead Sciences · Merck Sharp & Dohme LLC · National AIDS Control Organisation · National Institute on Drug Abuse (NIDA) · Research Institute for Development · University of California, San Diego · AIDS Malignancy Consortium · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · All India Institute of Medical Sciences · Amsterdam UMC, location VUmc · Ann & Robert H Lurie Children's Hospital of Chicago · Botswana Harvard Health Partnership · Botswana Ministry of Health · Brigham and Women's Hospital · CIHR Canadian HIV Trials Network · Chulalongkorn University · Cipla Medpro · Columbia University · Department of Foreign Affairs, Ireland · Dermatological Society of South Africa · Doris Duke Charitable Foundation · Guangdong Provincial Maternal and Child Health Hospital · HIV Prevention Trials Network · Health Research Board, Ireland · Hospital San Jaime de Calella · Hospital de Calella · Indian Council of Medical Research · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · International Antiviral Therapy Evaluation Center · Johns Hopkins Bloomberg School of Public Health · Kirby Institute · Liverpool School of Tropical Medicine · MEDEX · Mahidol University · Maternal and Child Health Hospital of Guangxi Province · Maternal and Child Health Hospital of Sichuan Province · Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region · Maternal and Child Health Hospital of Yunan Province · McGill University Health Centre/Research Institute of the McGill University Health Centre · Medecins Sans Frontieres, Netherlands · Ministry of Science and Technology of the People´s Republic of China · National Cancer Institute (NCI) · National Center for AIDS/STD Control and Prevention, China CDC · National Center for Women and Children's Health, China CDC · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institutes of Health (NIH) · National Research Foundation, Singapore · PENTA Foundation · Parexel · Peking Union Medical College · Princess Marina Hospital, Botswana · Ragon Institute of MGH, MIT and Harvard · Ratiopharm GmbH · Roxane Laboratories · St Vincent's Hospital, Sydney · Stanford University · Tibotec BVBA · Triangle Pharmaceuticals · Tuberculosis Research Centre, India · University Hospital, Caen · University of British Columbia · University of Cape Town · all 91 on the full record

Regulatory milestones approvals, filings & regulatory actions · 7 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	VIRAMUNE XR	—	2012-09-28	fda.gov ↗
Label expansions (4)	US (FDA)	VIRAMUNE	—	1998-05-20 – 2008-06-24	fda.gov ↗
Approved	EU (EMA)	Viramune	—	1998-02-04	europa.eu ↗
Approved	US (FDA)	VIRAMUNE	—	1996-06-21	fda.gov ↗

Trials 126 · started per year

today

US approved 1996

EU approved 1998

1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 125 trials
Phase 1	NCT02202005	Aug 2014 → Jul 2015	—	Ratiopharm GmbH	Completed	No outcome recorded
Phase 1	NCT02194218	Sep → Nov 2009	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00910806	Jun 2009 → Jun 2010	HIV infectious disease	Tibotec BVBA	Completed	No outcome recorded
Phase 1	NCT00905489	Jun 2009 → Sep 2012	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02184312	Apr → Jul 2008	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02194179	Dec 2006 → May 2007	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02192463	Apr → Aug 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02191189	May 2005 → Jan 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00307502	Jan 2005 → Dec 2009	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 1	NCT00730223	Mar 2004 → Mar 2006	HIV infectious disease	Vanderbilt University	Completed	No outcome recorded
Phase 1	NCT02184286	May 1999 → Feb 2000	HIV infectious disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 1	NCT02182765	Apr 1999 → Jul 2001	HIV infectious disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 1	NCT02184091	Jan → Jul 1999	impaired renal function disease, liver disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02182791	Apr 1998 → Apr 1999	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00001644	Mar 1997 → Feb 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002194	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00000814	? → Nov 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002381	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00000649	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00000902	? → Apr 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001091	? → Oct 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000808	? → Sep 1998	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00006279	? → May 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000962	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001108	? → Jun 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT02140255	Jan 2015 → Jan 2028 expected	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 1/2	NCT00672412	Oct 2008 → Jan 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT00312091	Dec 2006 → Sep 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT00260078	Feb 2006 → Apr 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 220 trials · 2 met primary
Phase 2	NCT02116660	Sep 2014 → Jul 2017	HIV infectious disease	Merck Sharp & Dohme LLC	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00640887	Feb 2009 → Oct 2010	HIV infectious disease, tuberculosis	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 2	NCT00109590	Jun 2006 → Oct 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00270296	Jun 2006 → Mar 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00307151	Dec 2005 → Dec 2010	HIV infectious disease	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	Met primary
Phase 2	NCT00146380	Jul 2003 → Jan 2009	HIV infectious disease	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 2	NCT00273975	Jan 2002 → Dec 2004	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00001688	Jan 1998 → Nov 2001	HIV infectious disease	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00000781	? → Sep 1996	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001095	? → Oct 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001083	? → Jun 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 2	NCT00002324	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00000872	? → Jan 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002347	—	HIV infectious disease	Parexel	Completed	No outcome recorded
Phase 2	NCT00002418	—	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 2	NCT00000747	? → Dec 1994	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000770	? → Nov 1994	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00021463	? → Feb 2002	HIV infectious disease, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000924	? → Jun 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001045	? → Oct 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/34 trials · 3 missed
Phase 2/3	NCT02369406	May 2015 → Nov 2020 overdue	AIDS	Harvard School of Public Health (HSPH)	Active not recruiting	No outcome recorded
Phase 2/3	NCT00495326	Dec 2007 → Apr 2011	AIDS, tuberculosis	French National Agency for Research on AIDS and Viral Hepatitis	Completed	Missed primary
Phase 2/3	NCT00624195	Mar 2007 → Feb 2012	HIV infectious disease	University of California, San Diego	Completed	Missed primary
Phase 2/3	NCT00039741	Aug 2002 → Aug 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 332 trials · 10 met primary · 7 missed
Phase 3	NCT01511237	Dec 2011 → Jun 2015	HIV infectious disease	Research Institute for Development	Completed	No outcome recorded
Phase 3	NCT00819052	Dec 2008 → Jan 2012	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00573001	Jul 2008 → Jul 2011	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 3	NCT00561925	Nov 2007 → Nov 2011	HIV infectious disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00427297	Sep 2007 → May 2009	HIV infectious disease	University of Washington	Terminated	No outcome recorded
Phase 3	NCT01805258	Jun 2007 → Dec 2012	tuberculosis	All India Institute of Medical Sciences	Completed	Missed primary
Phase 3	NCT00483054	Jan 2007 → Dec 2008	HIV infectious disease, tuberculosis	Bamrasnaradura Infectious Diseases Institute	Completed	No outcome recorded
Phase 3	NCT00074412	Jan 2007 → Sep 2011	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00089505	Nov 2006 → Aug 2010	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Met primary
Phase 3	NCT00332306	Jun 2006 → Jun 2009	HIV infectious disease, tuberculosis	Tuberculosis Research Centre, India	Unknown	No outcome recorded
Phase 3	NCT00102960	Jul 2005 → Sep 2012	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00117728	Apr 2005 → Sep 2010	AIDS	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Unknown	Met primary
Phase 3	NCT00199979	Apr 2005 → Jun 2008	immunodeficiency 79	MEDEX	Unknown	No outcome recorded
Phase 3	NCT00074581	Feb 2005 → May 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00639938	Jul 2004 → Jul 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00115648	Apr 2004 → Aug 2007	HIV infectious disease	Johns Hopkins Bloomberg School of Public Health	Completed	Met primary
Phase 3	NCT00099359	Feb 2004 → Feb 2011	HIV infectious disease	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 3	NCT00144183	Jan 2003 → Jan 2007	AIDS	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00197613	Dec 2002 → Dec 2007	AIDS	Harvard School of Public Health (HSPH)	Completed	No outcome recorded
Phase 3	NCT00061321	Aug 2002 → Apr 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00017719	May 2002 → Mar 2006	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00074399	Feb 2001 → Apr 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00398684	Jan 2001 → Jun 2004	HIV infectious disease	Research Institute for Development	Completed	Met primary
Phase 3	NCT02181933	Apr 1999 → Jan 2001	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00002368	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00006396	? → Nov 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00013520	? → Jun 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00002166	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00000869	? → May 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00001135	? → May 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00021671	? → Nov 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00000942	? → May 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 430 trials · 2 met primary
Phase 4	NCT06337032	Aug 2024 → Mar 2034 expected	HIV infectious disease	Gilead Sciences	Recruiting	No outcome recorded
Phase 4	NCT03642704	Feb 2017 → Sep 2019	—	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 4	NCT03088410	Aug 2016 → Mar 2022	HIV infectious disease, diabetes mellitus	Ann & Robert H Lurie Children's Hospital of Chicago	Completed	No outcome recorded
Phase 4	NCT02712801	Apr 2016 → Dec 2021	HIV infectious disease	National Center for Women and Children's Health, China CDC	Completed	No outcome recorded
Phase 4	NCT01637558	Nov 2012 → Jul 2017	HIV infectious disease, tuberculosis	University of Cape Town	Completed	No outcome recorded
Phase 4	NCT00753324	May 2009 → Jan 2012	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	Met primary
Phase 4	NCT00617643	May 2008 → Jun 2009	HIV infectious disease, tuberculosis	Makerere University	Completed	No outcome recorded
Phase 4	NCT00620438	Feb 2008 → Jul 2011	HIV infectious disease, tuberculosis	Makerere University	Unknown	No outcome recorded
Phase 4	NCT00523458	Jul 2007 → Mar 2008	HIV infectious disease, tuberculosis	Stanford University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00355719	Jan 2007 → Feb 2008	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 4	NCT00455585	Jan → May 2007	HIV infectious disease	Makerere University	Completed	No outcome recorded
Phase 4	NCT00618176	Jan 2005 → Sep 2006	HIV infectious disease	Peking Union Medical College	Completed	No outcome recorded
Phase 4	NCT00703898	Nov 2004 → Dec 2009	HIV infectious disease	Bamrasnaradura Infectious Diseases Institute	Completed	No outcome recorded
Phase 4	NCT00415090	Aug 2004 → Jul 2006	HIV infectious disease	Hospital de Calella	Completed	No outcome recorded
Phase 4	NCT00144248	Jun 2004 → Jun 2006	HIV infectious disease, liver disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00344461	Mar 2004 → Jul 2008	HIV infectious disease	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT00127972	Feb 2004 → Apr 2007	HIV infectious disease	International Antiviral Therapy Evaluation Center	Completed	No outcome recorded
Phase 4	NCT00144261	Nov 2003 → Dec 2006	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00122668	Nov 2003 → Jul 2005	HIV infectious disease, lipodystrophy	French National Agency for Research on AIDS and Viral Hepatitis	Terminated	No outcome recorded
Phase 4	NCT00405171	Jun 2003 → Feb 2006	HIV infectious disease, hyperlipoproteinemia	University Hospital, Caen	Completed	Met primary
Phase 4	NCT00144157	Jun 2003 → Jul 2006	AIDS	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00192660	Feb 2003 → Oct 2006	cardiovascular disorder, lipodystrophy	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00122226	Jan 2003 → Jul 2008	HIV infectious disease, lipodystrophy	Amsterdam UMC, location VUmc	Unknown	No outcome recorded
Phase 4	NCT00380770	Jan 2003 → Feb 2009	AIDS, Kaposi's sarcoma, human herpesvirus 8 infection	University of KwaZulu	Completed	No outcome recorded
Phase 4	NCT00143689	Apr 2002 → Feb 2008	HIV infectious disease	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT00273988	Apr 2002 → Oct 2003	AIDS	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274001	Sep 2001 → Mar 2004	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02181946	May → Jul 2001	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02184299	Apr 1999 → Jan 2000	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02184078	Oct → Dec 1998	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase not applicable11 trials · 2 missed
—	NCT00830856	Oct 2006 → Oct 2008	Cryptococcal meningitis, HIV infectious disease	University of Zimbabwe	Completed	Missed primary
—	NCT00028314	Mar 2002 → Mar 2005	HIV wasting syndrome, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00016601	Jun 2001 → May 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000922	? → Jan 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
—	NCT00087464	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00000896	? → Oct 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002407	—	HIV infectious disease	Weill Medical College of Cornell University	Completed	No outcome recorded
—	NCT00000895	? → Aug 2001	HIV infectious disease, Mycobacterium avium complex disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00001111	? → Jun 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000634	? → Jun 1995	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002323	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded

Comparator or background therapy47 trials
Phase 0	NCT00719602 Comparator	Aug 2009 → Aug 2013	HIV infectious disease, malaria	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	No outcome recorded
Phase 1	NCT00162149 Comparator	Oct 2005 → Jul 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00032669 Background	Mar 2002 → Apr 2006	HIV infectious disease	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00004580 Background	—	HIV infectious disease	Abbott	Completed	No outcome recorded
Phase 1/2	NCT01632891 Background	Jan 2014 → Jun 2016	HIV infectious disease, parasitemia	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Missed primary
Phase 2	NCT01789879 Comparator	Mar → Sep 2014	HIV infectious disease	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT01174914 Comparator	Mar 2008 → Mar 2010	—	The Ojai Foundation	Completed	No outcome recorded
Phase 2	NCT00099632 Background	Mar 2006 → Apr 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00294892 Comparator	Feb 2006 → Sep 2009	HIV infectious disease	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT00476853 Comparator	Oct 2005 → Sep 2008	HIV infectious disease, tuberculosis	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded
Phase 2	NCT00167674 Comparator	Nov 2003 → Mar 2005	HIV infectious disease	University of Washington	Completed	No outcome recorded
Phase 2/3	NCT02285114 Background	Jan 2015 → Nov 2019	—	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT03631732 Comparator	Aug 2018 → Aug 2019	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 3	NCT02616783 Comparator	Dec 2015 → Feb 2018	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 3	NCT02605954 Comparator	Nov 2015 → Jun 2017	HIV infectious disease	Gilead Sciences	Completed	Missed primary
Phase 3	NCT02469246 Background	Jun 2015 → Dec 2017	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 3	NCT02397096 Background	Jun 2015 → Feb 2018	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	Met primary
Phase 3	NCT02302547 Comparator	Dec 2014 → Aug 2017	HIV infectious disease	University Hospital, Tours	Completed	No outcome recorded
Phase 3	NCT02121795 Background	May 2014 → Aug 2015	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 3	NCT01435018 Background	Oct 2013 → Mar 2018	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Missed primary
Phase 3	NCT01495702 Comparator	Dec 2011 → Nov 2013	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01061151 Comparator	Mar 2011 → Sep 2016	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Mixed
Phase 3	NCT00978068 Comparator	Sep 2009 → Jan 2013	HIV infectious disease, malaria	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT00409591 Comparator	Jul 2008 → Nov 2010	HIV infectious disease	Research Institute for Development	Terminated	Missed primary
Phase 3	NCT00389207 Comparator	Oct 2006 → Feb 2011	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00234091 Comparator	Apr 2006 → Sep 2011	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00164736 Comparator	Mar 2004 → Jan 2010	HIV infectious disease	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 3	NCT00004581 Background	—	HIV infectious disease	Abbott	Completed	No outcome recorded
Phase 4	NCT07014189 Comparator	Apr 2019 → Jan 2023	HIV infectious disease	Cantonal Hospital of St. Gallen	Completed	No outcome recorded
Phase 4	NCT02431975 Background	Aug 2015 → Apr 2020	HIV infectious disease	Columbia University	Completed	No outcome recorded
Phase 4	NCT01694017 Comparator	Nov 2012 → Aug 2014	HIV infectious disease	Tufts University	Completed	No outcome recorded
Phase 4	NCT01192035 Comparator	May 2011 → Sep 2014	—	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT01340950 Comparator	Jul 2010 → Jul 2014	HIV infectious disease, central nervous system disorder, dementia	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT01772940 Comparator	Dec 2008 → Oct 2011	HIV infectious disease	Centre Hospitalier Universitaire Saint Pierre	Completed	Missed primary
Phase 4	NCT00661349 Comparator	Feb → Dec 2008	HIV infectious disease	Germans Trias i Pujol Hospital	Terminated	No outcome recorded
Phase 4	NCT00552240 Comparator	Sep 2007 → Mar 2010	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00540137 Comparator	Jul 2007 → Dec 2012	HIV infectious disease	Imperial College London	Completed	No outcome recorded
Phase 4	NCT02028676 Comparator	Mar 2007 → Mar 2012	HIV infectious disease	Medical Research Council	Completed	No outcome recorded
Phase 4	NCT00704249 Comparator	Jul 2006 → Jul 2008	HIV infectious disease	Clinical Trial Agency of HIV Study Group	Completed	No outcome recorded
Phase 4	NCT00335686 Comparator	Oct 2003 → Mar 2006	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
—	NCT03664440 Comparator	Dec 2016 → Oct 2017	—	Mahidol University	Completed	No outcome recorded
—	NCT02002286 Background	Aug 2011 → May 2013	HIV infectious disease	LI Taisheng	Completed	No outcome recorded
—	NCT01277627 Comparator	Jan 2011 → Jul 2012	hepatitis C virus infection	Valme University Hospital	Unknown	No outcome recorded
—	NCT00428116 Comparator	Sep 2007 → Jul 2013	HIV infectious disease	University of Washington	Terminated	No outcome recorded
—	NCT00255840 Comparator	Jul 2006 → Jan 2009	HIV infectious disease	CIPRA SA	Completed	No outcome recorded
—	NCT00197587 Comparator	Aug 2002 → May 2005	HIV infectious disease	Harvard School of Public Health (HSPH)	Completed	No outcome recorded
—	NCT00004855 Background	? → Apr 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 2

Date	Issuer	Release
2011-04-04	Boehringer Ingelheim	Regulatory FDA Approves One-Pill, Once-Daily Viramune® XR™ (nevirapine) Extended-Release Tablets for Use in Combination With Other Antiretroviral Agents for Treatment of HIV-1 Infection in Adults prnewswire.com ↗
2010-07-22	Boehringer Ingelheim	Results Study Shows Once-Daily, Extended-Release Formulation of Nevirapine was not Inferior to Twice-Daily VIRAMUNE in Treatment-Naive HIV-1 Infected Patients prnewswire.com ↗ The investigational, extended-release formulation of nevirapine had a similar safety profile to immediate release VIRAMUNE in the trial.

All press releases naming this drug 3 releases

Date	Issuer	Release
2011-04-04	Boehringer Ingelheim	FDA Approves One-Pill, Once-Daily Viramune® XR™ (nevirapine) Extended-Release Tablets for Use in Combination With Other Antiretroviral Agents for Treatment of HIV-1 Infection in Adults prnewswire.com ↗
2010-07-22	Boehringer Ingelheim	Study Shows Once-Daily, Extended-Release Formulation of Nevirapine was not Inferior to Twice-Daily VIRAMUNE in Treatment-Naive HIV-1 Infected Patients prnewswire.com ↗
2002-10-15	Aspen USA Inc	Boehringer Ingelheim grants a voluntary license for nevirapine to South African company Aspen Pharmacare aspenpharma.com ↗

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 185 sources stand behind the page.

Field	Value	Cited text
Known as	nevirapine	“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ 172 “It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗ “Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.” NCT02002286 ↗ “The study-treatment were lopinavir/r 100/400mg bid or indinavir/r 100/400mg bid for PI-class, for NNRTI-class, efavirenz or nevirapine and all NRTIs except D4T and DDC at usual dosage.” NCT00122668 ↗ “Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)” NCT00380770 ↗ “Tenofovir+Emtricitabine+Third agent (Including a non nucleoside reverse transcriptase inhibitor: efavirenz or nevirapine or etravirine or rilpivirine” NCT02302547 ↗ “Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular” NCT02397096 ↗ “nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection.” NCT03642704 ↗ “Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects” NCT02194179 ↗ “efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP)” NCT02469246 ↗ “Allowed unboosted 3rd ARV agents: efavirenz (EFV), raltegravir (RAL), dolutegravir (DTG), or nevirapine (NVP)” NCT02285114 ↗ Show 162 more sources
Known as	BI-RG-587	“An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3” NCT00000747 ↗ 3 “Nevirapine (BI-RG-587) has shown in vitro inhibitory activity against HIV-1 reverse transcriptase (RT).” NCT00000962 ↗ “Nevirapine (BI-RG-587) has shown in vitro inhibitory activity against HIV-1 reverse transcriptase” NCT00001111 ↗ “nevirapine (BI-RG-587) plasma levels” NCT00000634 ↗
Known as	BIRG 0587	ChEMBL registry synonym — accepted as the source's own label CHEMBL57 ↗
Known as	Neviparine	“Neviparine (NVP)/ Lamivudine (3TC)” NCT07014189 ↗
Known as	Nevirapina	ChEMBL registry synonym — accepted as the source's own label CHEMBL57 ↗
Known as	Nevirapine anhydrous	ChEMBL registry synonym — accepted as the source's own label CHEMBL57 ↗
Known as	Nevirapine teva	ChEMBL registry synonym — accepted as the source's own label CHEMBL57 ↗
Known as	Nevirapinum anhydrous	ChEMBL registry synonym — accepted as the source's own label CHEMBL57 ↗
Known as	NSC-641530	ChEMBL registry synonym — accepted as the source's own label CHEMBL57 ↗
Known as	NVP	“The objective was to establish the pharmacokinetic (PK) profile at steady state of two different nevirapine (NVP) extended release (XR) formulations at 300 mg or 400 mg daily...” NCT02194179 ↗ 57 “In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine,...” PMID 11372025 ↗ May 2001 “The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine...” PMID 11840078 ↗ Feb 2002 “The purpose of this study is to see if nevirapine (NVP) or zidovudine (AZT), given to mothers during labor and delivery and to their babies during the first week of life, can...” NCT00006396 ↗ “Patients in Arm B-1 will discontinue their current HAART and will receive a PI and a nonnucleoside reverse transcriptase inhibitor (NNRTI), either lopinavir/ritonavir (LPV/r)...” NCT00028314 ↗ “An open-label phase 1/2 study was designed to assess the safety and trough concentrations of nevirapine (NVP) given once weekly (OW), twice weekly (TW), or once daily (OD) to...” PMID 14657758 ↗ Dec 2003 “Treatment-naive adults were randomized to nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r) regimens each in combination with tenofovir (TDF)/emtricitabine (FTC) or...” PMID 25028911 ↗ May 2014 “The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1)” NCT00294892 ↗ “The 7 drugs that will be given in this study are stavudine (d4T), didanosine (ddI), lamivudine (3TC), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and nevirapine (NVP).” NCT00001108 ↗ “Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed in human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB).” PMID 21890776 ↗ Oct 2011 “Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV).” PMID 23300238 ↗ Jan 2013 Show 47 more sources
Known as	NVP IR	“The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release...” NCT00561925 ↗
Known as	NVP XR	“The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release...” NCT00561925 ↗
Known as	NVP: nevirapine, Viramune	“NVP: nevirapine, Viramune” NCT02028676 ↗
Known as	Viramune	“An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS...” NCT00002368 ↗ 18 “An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1...” NCT00002381 ↗ “The purpose of this trial is to compare the effect of switching to nevirapine (Viramune®)-containing regimen on quality of life of patients with fat abnormalities and...” NCT00274001 ↗ “The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1)” NCT00294892 ↗ “A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy” NCT00273988 ↗ “An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease” NCT00002166 ↗ “An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.” NCT00002194 ↗ “Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients” NCT02184078 ↗ “lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;” NCT00143689 ↗ “Nevirapine (Viramune): tablets 200 mg (1 tablet/12h\*)” NCT00355719 ↗ “Nevirapine (Viramune): 1 comp (200mg)/12h” NCT00335686 ↗ Show 8 more sources
Known as	Viramune (nevirapine)	“Viramune (nevirapine)” NCT00523458 ↗
Known as	Viramune (Nevirapine) suspension 50mg/5ml	“Viramune (Nevirapine) suspension 50mg/5ml” NCT00164736 ↗
Known as	Viramune xr	ChEMBL registry synonym — accepted as the source's own label CHEMBL57 ↗
Action	Inhibit	“Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction) of HIV.” NCT00000634 ↗
Modality	Small molecule	“non-nucleoside reverse transcriptase inhibitor” NCT00000781 ↗
Route	Oral	“Two doses, given by mouth, are evaluated” NCT00000634 ↗